IRCT20240120060741N1
Recruiting
Phase 3
Clinical trial of the immunogenicity and safety of Papilloguard 4 vaccine (quadrivalent manufactured by Nivad Pharmed Salamat company) compared to Gardasil vaccine (quadrivalent, reference product, Merck company) by comparing the ratio of GMT (Geometric Mean Titer) in healthy male and female volunteers 15 to 25 years: a phase 3 randomized, parallel, double-blind, noninferiority clinical trial
ivad Pharmed Salamat0 sites670 target enrollmentTBD
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Genital wart prevention.
- Sponsor
- ivad Pharmed Salamat
- Enrollment
- 670
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Males and females 15 to 25 years old
- •Eligible for general health (through clinical examinations and medical records)
- •Signed the informed consent form (or guardian has signed the informed consent form)
- •It is possible to accompany the visit programs and the study process within 7 months
- •Not having fever (above 37\.5°C) or acute infectious disease within 24 hours of participation
- •If the female volunteer had sex within two weeks before entering the study, she must have used a suitable method of prevention (other than emergency pills)
- •Women volunteer must not be pregnant and should agree to use effective preventive method through 7 months of the study
- •Not having a plan to inject other vaccines in the study period (except Meningococcal, hepatitis B, influenza, diphtheria/tetanus vaccines, or injection of diphtheria/tetanus vaccine 8 days before participation with the prior consultation of PI).
Exclusion Criteria
- •Received any prior doses of HPV vaccine
- •A history of severe allergic reactions (swelling of the mouth and throat, dyspnea, hypotension, urticaria, shock) that require therapeutic interventions.
- •History of alcohol or drug abuse (addiction) within 1 year before entering the study
- •Subjects who are thrombocytopenic or suffering from any coagulation disorder that prohibits intramuscular injection.
- •Breastfeeding women
- •Subjects with immune\-mediated disease include: splenectomy, subjects who have immune disorders (e.g. lupus, rheumatoid arthritis), currently taking immunosuppressant medication (including radiation therapy, anti\-metabolites, taking systemic corticosteroids in the last three weeks more than 15 mg daily), people who are currently undergoing chemotherapy
- •History of chronic diseases e.g. cancer, liver and kidney diseases, chronic lung disease, heart failure, thyroid disorders, neurologic disorders, diabetes, autoimmune disease
- •Receiving immunoglobulins or blood products within 6 months before participation and not having a plan to receive through 7 months of the study.
- •Any other condition outside of the above that, in the opinion of the researcher/doctor, makes the candidate unsuitable for participating in the clinical trial.
- •Participation in other clinical trials
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Study for effects of Haemophilus Influenzae type b conjugate vaccine in childreChildren Haemophilus Meningitis.Meningitis due to Haemophilus influenzaeIRCT201008084536N1Masoondarou Co.50
Active, not recruiting
Phase 1
Immunogenicity of anti-pneumococcal vaccination in acute leukemia and lymphomaEUCTR2020-002017-18-FRCHU DE POITIERS160
Recruiting
Phase 1
evaluate the safety and immunomodulatory efficacy of Byolic CC supplementImmunomodulatory effect on healthy volunteers.IRCT20240304061158N4Behpad Teb Iranian90
Completed
Not Applicable
A safety and immunogenicity phase 1 trial with an adjuvated TB subunit vaccine (Ag85B - ESAT-6 + IC31) administered in PPD positive volunteers at 0 and 2 monthsPreventionTuberculosis10028440NL-OMON30684Statens Serum Institut20
Completed
Phase 3
A Comparative Phase III Clinical Study of Bharat Biotech International Limited Rabies Vaccine INDIRAB reconstituted with 1mL diluent Vs Reference Vaccine, administered Intramuscularly in healthy volunteers as Pre-Exposure treatment.CTRI/2010/091/000214Bharat Biotech International Limited,Genome Valley, Shameerpet,Ranga Reddy (Distict),Hyderabad-500 078.60